Blog
RSS FeedPosted by Michael Wonder on 15 Dec 2016
Decision relating to anti-VEGF treatments for ophthalmic use
15 December 2016 - On 5 September 2016, PHARMAC consulted on a proposal to list ranibizumab (Lucentis) and aflibercept (Eylea) ...
Posted by Michael Wonder on 15 Dec 2016
Health Canada approves Stelara for the treatment of adults with moderately to severely active Crohn's disease
14 December 2016 - Stelara offers a new approach to treating Crohn's disease in Canada, which has one of the ...
Posted by Michael Wonder on 15 Dec 2016
Health Canada approves CSL Behring’s Afstyla for the treatment of haemophilia A
14 December 2016 - Afstyla is the first and only single-chain recombinant factor VIII for haemophilia A, specifically designed for ...
Posted by Michael Wonder on 15 Dec 2016
European Commission grants Intercept's Ocaliva (obeticholic acid) marketing authorisation for the treatment of primary biliary cholangitis
14 December 2016 - Intercept Pharmaceuticals today announced that the European Commission has granted conditional approval for Ocaliva (obeticholic acid) ...
Posted by Michael Wonder on 14 Dec 2016
Ferring receives EU approval for Rekovelle (follitropin delta)
13 December 2016 - A novel human recombinant follicle stimulating hormone administered using an individualised dosing regimen. ...
Posted by Michael Wonder on 14 Dec 2016
FDA approves Eucrisa for eczema
14 December 2016 - The U.S. FDA today approved Eucrisa (crisaborole) ointment to treat mild to moderate eczema (atopic dermatitis) in ...
Posted by Michael Wonder on 14 Dec 2016
NICE publishes final guidance on the use of AstraZeneca's Brilique
14 December 2016 - The guidance relates to the use of ticagrelor for the prevention of atherothrombotic events after myocardial ...
Posted by Michael Wonder on 14 Dec 2016
New formulation of Rituxan now available to Canadians living with non-Hodgkin's lymphoma
13 December 2016 - Canadians living with non-Hodgkin's lymphoma, one of the most commonly diagnosed blood cancers in Canada, now have ...
Posted by Michael Wonder on 13 Dec 2016
FDA approves first autologous cellularized scaffold for the repair of cartilage defects of the knee
14 December 2016 - The U.S. FDA today approved Maci (autologous cultured chondrocytes on porcine collagen membrane) for the repair of ...
Posted by Michael Wonder on 13 Dec 2016
European Commission grants marketing authorization for Arzerra (ofatumumab) in combination with fludarabine and cyclophosphamide in relapsed CLL
12 December 2016 - Approval based on data from Phase III COMPLEMENT 2 trial. ...
Posted by Michael Wonder on 13 Dec 2016
Pediapharm receives Health Canada approval for Otixal
12 December 2016 - Pediapharm is very pleased to announce Health Canada's approval of Otixal (ciprofloxacin 0.3 % and fluocinolone ...
Posted by Michael Wonder on 13 Dec 2016
Emergent BioSolutions receives Health Canada approval for botulism anti-toxin
12 December 2016 - Emergent BioSolutions today announced that Health Canada has approved the company’s new drug submission for its botulism ...
Posted by Michael Wonder on 12 Dec 2016
U.S. FDA approves Synjardy XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes
12 December 2016 - New once-a-day formulation indicated to improve blood sugar when used along with diet and exercise ...
Posted by Michael Wonder on 12 Dec 2016
Scots miss out on breast cancer drug ‘withheld’ from NHS use
12 December 2016 - Scottish women will miss out on a drug that can shrink breast cancer tumours before surgery, ...
Posted by Michael Wonder on 12 Dec 2016
SMC - December 2016 decisions
12 December 2016 - The Scottish Medicines Consortium has today published advice accepting a medicine used to treat advanced prostate ...